MEDIGARD BLOOD-DEVICE LAUNCH HITS A SNAG

Written on the 15 May 2015 by Jenna Rathbone

MEDIGARD BLOOD-DEVICE LAUNCH HITS A SNAG

MEDIGARD'S (ASX:MGZ) unique blood collection device is yet to hit shelves, despite two announcements that initial sales for the medical instrument would commence in March of this year.

The Gold Coast company, which has again delayed the launch, says it is a result of market resistance to primary packaging and unexpected delays occurring while trying to implement a solution.

Although significant resources had been employed to produce a blood collection device (BCD) that requires no primary packaging, it is now expected that sales for the BCD will commence in June.

Medigard says at the time of announcing a March launch date it was convinced the changes made to the device to allow it to be manufactured and distributed without primary packaging would not cause significant further delays.

"Although the changes are not obvious from appearance, the subtle design changes and the changes to the materials used for the moulding of some key components has also meant that manufacturing equipment has had to be modified," says Medigard in a statement to shareholders.

"As is the nature of medical device design changes, there has had to be changes to the regulatory approvals for the BCD.  Both of these factors have caused unexpected delays."

Small-scale manufacture is currently under way and the BCD is expected to launch in Taiwan and Asia Pacific in June and the US and Europe in July.

Medigard says 300,000 BCDs are currently in production and will be distributed for clinical evaluations. A clinical study is to be coordinated in the UK.

The Medigard BCD features vacuum technology to capture the needle after blood has been collected.  This is expected to prevent needle-stick injury by eliminating human contact with used needles and avoids potential aerosoling, a dangerous spray of fluid getting into the air when a needle is retracted.

In 2013, Medigard secured an exclusive license agreement with Shanghai Sol-Millennium Medical Products Co to manufacture and distribute its BCD and Blood Flash Needle.

Medigard has patents for the BCD in Australia, the US, Japan, Canada and Europe while the 3ml vacuum retractable syringe has patents in South Africa, the US, Australia, China, Japan and Canada.

Medigard was floated in 2004 and its board includes Don Channer as chairman and Peter Clark as director.

Shares closed at .085c. 


Author: Jenna Rathbone
About: Jenna Rathbone is a Queensland-based journalist who writes on a range of issues including business and property affairs and social issues.
Connect via: Twitter

Latest News

SLATER AND GORDON TAKES SPOTLESS TO COURT

SPOTLESS Group (ASX: SPO) has been hit by a class action launched by Slater and Gordon (ASX: SGH) in the Federal C...

ANSELL'S SHARE PRICE SWELLS AFTER SALE OF CONDOM BUSINESS

IT'S one of Australia's most successful and enduring manufacturing success stories and the Ansell condom busi...

TOPSHOP GOES INTO ADMINISTRATION AMID VOLATILE RETAIL MARKET

TOPSHOP has become the latest in a string of retailers blasted by the volatile retail market, as the iconic fashio...

SIGMA'S SHARE PRICE TAKES A BATTERING AS IT LAUNCHES LEGAL ACTION OVER SUPPLY DEAL

SIGMA Healthcare (ASX: SIG) has taken the MyChemist and Chemist Warehouse chains to court to demand they continue to ...

Related News

SLATER AND GORDON TAKES SPOTLESS TO COURT

SPOTLESS Group (ASX: SPO) has been hit by a class action launched by Slater and Gordon (ASX: SGH) in the Federal C...

TOPSHOP GOES INTO ADMINISTRATION AMID VOLATILE RETAIL MARKET

TOPSHOP has become the latest in a string of retailers blasted by the volatile retail market, as the iconic fashio...

SIGMA'S SHARE PRICE TAKES A BATTERING AS IT LAUNCHES LEGAL ACTION OVER SUPPLY DEAL

SIGMA Healthcare (ASX: SIG) has taken the MyChemist and Chemist Warehouse chains to court to demand they continue to ...

REGIONAL BANKS HIT OUT AT RATING CUT AND WARN BIG FOUR WILL BENEFIT

REGIONAL banks have hit out at a downgrade on their credit ratings, warning that it will increase their wholesale fun...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter